Tempest Therapeutics, Inc. (TPST)

NCM – Цена в реальном времени. Валюта: USD

1.08

+0.03 (2.86%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

1.08

0.00 (0.00%)

После закрытия: Jun 26, 2026, 7:08 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Tempest Therapeutics, Inc. (TPST)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Видео

No Data

Пресс-релизы

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Search stocks

Tempest Therapeutics, Inc. (TPST)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Видео

No Data

Пресс-релизы

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting